- Home
- SLP vs MREO Comparison
SLP vs MREO Comparison
Compare SLP & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLP
- MREO
- Stock Information
- Founded
- SLP 1996
- MREO 2015
- Country
- SLP United States
- MREO United Kingdom
- Employees
- SLP N/A
- MREO N/A
- Industry
- SLP EDP Services
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- SLP Technology
- MREO Health Care
- Exchange
- SLP Nasdaq
- MREO Nasdaq
- Market Cap
- SLP 322.4M
- MREO 311.8M
- IPO Year
- SLP 1997
- MREO N/A
- Fundamental
- Price
- SLP $18.16
- MREO $2.00
- Analyst Decision
- SLP Buy
- MREO Strong Buy
- Analyst Count
- SLP 8
- MREO 5
- Target Price
- SLP $26.80
- MREO $7.40
- AVG Volume (30 Days)
- SLP 516.8K
- MREO 1.5M
- Earning Date
- SLP 12-01-2025
- MREO 11-11-2025
- Dividend Yield
- SLP N/A
- MREO N/A
- EPS Growth
- SLP N/A
- MREO N/A
- EPS
- SLP N/A
- MREO N/A
- Revenue
- SLP $80,383,000.00
- MREO $500,000.00
- Revenue This Year
- SLP $12.65
- MREO N/A
- Revenue Next Year
- SLP $2.92
- MREO $72.16
- P/E Ratio
- SLP N/A
- MREO N/A
- Revenue Growth
- SLP 20.01
- MREO N/A
- 52 Week Low
- SLP $12.39
- MREO $1.47
- 52 Week High
- SLP $37.67
- MREO $4.42
- Technical
- Relative Strength Index (RSI)
- SLP 67.01
- MREO 55.18
- Support Level
- SLP $17.28
- MREO $1.98
- Resistance Level
- SLP $18.41
- MREO $2.28
- Average True Range (ATR)
- SLP 0.86
- MREO 0.11
- MACD
- SLP 0.25
- MREO -0.01
- Stochastic Oscillator
- SLP 97.01
- MREO 41.83
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).